PMID- 35654421
OWN - NLM
STAT- MEDLINE
DCOM- 20230515
LR  - 20230515
IS  - 1471-1788 (Electronic)
IS  - 1365-1501 (Linking)
VI  - 27
IP  - 1
DP  - 2023 Mar
TI  - Impact of early use of long-acting injectable antipsychotics on functional 
      outcome in first episode psychosis: a 3-year longitudinal study.
PG  - 25-34
LID - 10.1080/13651501.2022.2079531 [doi]
AB  - OBJECTIVES: To describe, in a naturalistic setting, the impact of the early use 
      of LAI-AP on functional outcomes of early psychosis patients as compared to oral 
      antipsychotics (OAP). METHODS: Longitudinal prospective 3-year naturalistic study 
      of all consecutive admissions (n = 416) to two Early intervention services (EIS) 
      for psychosis comparing baseline characteristics and the evolution of global 
      functioning, occupation (work and studies), and living arrangements autonomy 
      according to the route of administration of the antipsychotic medication. The 
      cohort was divided into four groups: LAI-AP first (started on LAI-AP and later 
      received OAP), OAP first, LAI-AP only, and OAP only. RESULTS: Global assessment 
      of functioning (GAF) improved in all groups, but our mixed-effect model did not 
      show any significant association between the route of administration and the GAF 
      outcome. The LAI-AP only group was significantly less likely to have extreme 
      residential instability at 3 years than the other groups despite its highest 
      proportion of homeless youth and their poor prognostic factors at baseline. 
      CONCLUSIONS: Our naturalistic study suggests a significant protective effect of 
      LAI-AP on extreme residential instability for the most vulnerable patients, but 
      no impact of the first AP administration route on other functional outcomes was 
      observed at 3 years of follow-up. Key pointsLong-acting injectable antipsychotics 
      seem promising to avoid extreme residential instability in early psychosis.Global 
      assessment of functioning (GAF) improved in all groups.There was no significant 
      association between the first route of administration and global functionning.
FAU - Abdel-Baki, Amal
AU  - Abdel-Baki A
AD  - Clinique JAP, Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal, 
      Canada.
AD  - Department of Psychiatry and Addictology, Universite de Montreal, Montreal, 
      Canada.
AD  - CHUM Research Centre, Montreal, Canada.
FAU - Poulin, Emile
AU  - Poulin E
AD  - Department of Psychiatry and Addictology, Universite de Montreal, Montreal, 
      Canada.
FAU - Medrano, Sofia
AU  - Medrano S
AD  - CHUM Research Centre, Montreal, Canada.
FAU - Pires de Oliveira Padilha, Paula
AU  - Pires de Oliveira Padilha P
AD  - CHUM Research Centre, Montreal, Canada.
FAU - Stip, Emmanuel
AU  - Stip E
AD  - Department of Psychiatry and Addictology, Universite de Montreal, Montreal, 
      Canada.
AD  - CHUM Research Centre, Montreal, Canada.
AD  - Department of Psychiatry and Behavioral Sciences, College of Medicine, United 
      Arab Emirates University, Al Ain, United Arab Emirates.
FAU - Potvin, Stephane
AU  - Potvin S
AD  - Department of Psychiatry and Addictology, Universite de Montreal, Montreal, 
      Canada.
AD  - Centre de Recherche Fernand-Seguin, Institut Universitaire en Sante Mentale de 
      Montreal, Montreal, Canada.
LA  - eng
PT  - Journal Article
DEP - 20220602
PL  - England
TA  - Int J Psychiatry Clin Pract
JT  - International journal of psychiatry in clinical practice
JID - 9709509
RN  - 0 (Antipsychotic Agents)
RN  - 0 (Delayed-Action Preparations)
SB  - IM
MH  - Humans
MH  - Adolescent
MH  - *Antipsychotic Agents/adverse effects
MH  - Longitudinal Studies
MH  - *Schizophrenia/drug therapy
MH  - Prospective Studies
MH  - *Psychotic Disorders/drug therapy
MH  - Delayed-Action Preparations/pharmacology
OTO - NOTNLM
OT  - Schizophrenia
OT  - employment
OT  - first-episode psychosis
OT  - functional outcome
OT  - homelessness
OT  - long-acting injectable antipsychotic
EDAT- 2022/06/03 06:00
MHDA- 2023/05/15 06:42
CRDT- 2022/06/02 19:43
PHST- 2023/05/15 06:42 [medline]
PHST- 2022/06/03 06:00 [pubmed]
PHST- 2022/06/02 19:43 [entrez]
AID - 10.1080/13651501.2022.2079531 [doi]
PST - ppublish
SO  - Int J Psychiatry Clin Pract. 2023 Mar;27(1):25-34. doi: 
      10.1080/13651501.2022.2079531. Epub 2022 Jun 2.